Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen to use ProteinChips in Toxicology Project with Pfizer


Ciphergen Biosystems signed an agreement this week with Pfizer to use its ProteinChip system in a study to identify protein biomarkers associated with drug safety, the companies said.

The study will use serum from rat models, and look for proteins in the serum that could be identified as associated with a toxic response to a medication. Ciphergen will conduct these studies in its Biomarker centers in California, Pennsylvania, and Denmark.

This initial project, if successful, could be expanded into a larger program, according to Ciphergen CEO William Rich.

Ciphergen’s ProteinChip has a hydrophilic polymer surface, in which surface proteins bind to proteins screened from a sample. Currently, the company has a collaboration with Applied Biosystems to provide a ProteinChip interface for mass spectrometers.

The company’s other ProteinChip customers include AstraZeneca, BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, and Pharmacia. Currently, the company has a co-distribution agreement with Invitrogen.


The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.